Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma

Phase 2 Completed 36 enrolled Massachusetts General Hospital National Comprehensive Cancer Network · collab Peregrine Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

This research study is studying a combination of drugs with radiation as a possible treatment for Glioblastoma. The drugs involved in this study are: * Bavituximab * Temozolomide

Timeline

Start: 2017-09-13
Primary completion: 2022-08-31
Completion: 2022-08-31

Outcome

Met primary endpoint

paper The study met its primary endpoint with an OS-12 of 73% (95% confidence interval, 59%-90%). PMID 37327319 ↗

Publications

Ly KI, Richardson LG, Liu M, Muzikansky A, Cardona J, Lou K, Beers AL, Chang K, Brown JM, Ma X, Reardon DA, Arrillaga-Romany IC, Forst DA, Jordan JT, Lee EQ, Dietrich J, Nayak L, Wen PY, Chukwueke U, Giobbie-Hurder A, Choi BD, Batchelor TT, Kalpathy-Cramer J, Curry WT, Gerstner ER. Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients. Clin Cancer Res. 2023 Aug 15;29(16):3017-3025. doi: 10.1158/1078-0432.CCR-23-0203.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bavituximab	Monoclonal antibody	3 mg/kg	Intravenous
Background	Temozolomide	Small molecule	150 mg/m2	Oral
Background	Temozolomide	Small molecule	200 mg/m2	Oral